42027-81-6

Basic information

• Product Name: 1-hydroxyethyl-4-nitropyrazole
• Synonyms: 1-hydroxyethyl-4-nitropyrazole;1-(2-Hydroxyethyl)-4-nitro-1H-pyrazole;1beta-Hydroxyethyl-4-nitropyrazole;M and B 4998;2-(4-Nitro-1H-pyrazol-1-yl)
• CAS NO: 42027-81-6
• Molecular Formula: C₅H₇N₃O₃
• Molecular Weight: 157.13
• Mol File: 42027-81-6.mol

Chemical Properties

• Melting Point: 92-94℃
• Boiling Point: 343.5°C at 760 mmHg
• Flash Point: 161.6°C
• Appearance: /
• Density: 1.53
• Vapor Pressure: 2.67E-05mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-hydroxyethyl-4-nitropyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-hydroxyethyl-4-nitropyrazole(42027-81-6)
• EPA Substance Registry System: 1-hydroxyethyl-4-nitropyrazole(42027-81-6)

Safety Data

• Hazardous Substances Data: 42027-81-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Hydroxyethyl-4-nitropyrazole is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique molecular structure allows it to be a versatile building block in the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Industry:
1-Hydroxyethyl-4-nitropyrazole is used as an agrochemical intermediate for the synthesis of pesticides and other agrochemical products. Its potential biological activity makes it a promising candidate for the development of new agrochemicals with improved efficacy and selectivity.
Used in Materials Science:
1-Hydroxyethyl-4-nitropyrazole is used as a component in the development of new materials with unique properties. Its ability to participate in various chemical reactions allows it to be incorporated into the synthesis of advanced materials for applications in areas such as electronics, coatings, and adhesives.
Further research and development of 1-Hydroxyethyl-4-nitropyrazole may lead to the discovery of new applications and potential uses in different industries, expanding its utility and impact on various fields.

InChI:InChI=1/C5H7N3O3/c9-2-1-7-4-5(3-6-7)8(10)11/h3-4,9H,1-2H2

Upstream product

• 2075-46-9 4-nitro-1H-pyrazole 
• 540-51-2 2-bromoethanol 
• 1346672-86-3 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-nitro-1H-pyrazole 
• 1333960-64-7 2-[4-(4-amino-6-methylpyrimidin-2-yl)piperazin-1-yl]ethanol 

Downstream Products

• 948571-47-9 2-(4-amino-1H-pyrazol-1-yl)ethan-1-ol 
• 1421856-75-8 C₂₂H₂₁F₂N₇O₃ 
• 948570-74-9 1-(2-methoxyethyl)-1H-pyrazole-4-amine 
• 948570-75-0 1-(2-methoxyethyl)-4-nitro-1H-pyrazole 
• 1394161-75-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(4,6-dimethoxy-pyrimidin-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394161-09-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(benzo[1,3]dioxol-5-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394162-45-8 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl 4-methyl-benzenesulfonate 
• 1394162-44-7 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl methanesulfonate 
• 1394162-42-5 N-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide 

Relevant articles and documents

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis

Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favourable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokinestimulated cellular analysis, compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biological studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these experimental explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis.

Preparation method and application of novel 6-amino-1H-pyrazolo[3,4-d]pyrimidine JAK kinase inhibitors

The present invention provides drugs used for preventing, treating and/or ameliorating autoimmune diseases (such as psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Sjogren's syndrome, Behcet's disease, multiple sclerosis and systemic lupus erythematosus). The drugs have excellent JAK kinase inhibitory activity. The present invention also provides pharmaceutically acceptable compositions including the above compounds, and methods for preparing the compounds.

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors

Janus kinases (JAKs) play a key role in the proliferation, apoptosis and differentiation of immune cells, and JAKs are considered as an attractive target for the treatment of inflammatory and autoimmune diseases. Here we show the design and optimization of pyrimidine-4,6-diamine derivatives as selectivity JAK3 inhibitors. Compound 11e, which might interact with unique cysteine (Cys909) residue in JAK3, exhibited excellent JAK3 inhibitory activity (IC50 = 2.1 nM) and high JAK kinase selectivity. In cellular assay, 11e showed moderate potency inhibiting IL-2-stimulated T cell proliferation. The data supports the further development of novel JAKs inhibitors.

Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors

A series of 4-aminoquinazolines derivatives containing hydrophilic group were designed and identified as potent Pan-PI3K inhibitors in this study. The results of antiproliferative assays in vitro showed that this series of compounds had strong inhibition of tumor growth, especially compound 7b for MCF-7 cells but weak inhibition to normal cells. PI3K kinase assay showed that 7b had high activity for three PI3K isoforms with the IC50 values of picomole. The western blot assay indicated that 7b could decrease the phospho-Akt (S473) in a dose-dependent manner. Further experiments showed that 7b could induce apoptosis in MCF-7 cells. Four key hydrogen bonding interactions were found in the docking of 7b with PI3K kinase. All these results suggested that 7b is a potent PI3K inhibitor and could be considered as a potential candidate for the development of anticancer agents.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHBITION OF ERK5

The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

IRAK INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.